Gene: UBQLN2
Official Full Name: ubiquilin 2provided by HGNC
Gene Summary: This gene encodes an ubiquitin-like protein (ubiquilin) that shares high degree of similarity with related products in yeast, rat and frog. Ubiquilins contain a N-terminal ubiquitin-like domain and a C-terminal ubiquitin-associated domain. They physically associate with both proteasomes and ubiquitin ligases; and thus, are thought to functionally link the ubiquitination machinery to the proteasome to affect in vivo protein degradation. This ubiquilin has also been shown to bind the ATPase domain of the Hsp70-like Stch protein. [provided by RefSeq, Oct 2009]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO26872 | UBQLN2 Knockout cell line (HeLa) | Human | UBQLN2 | 1:3~1:6 | Negative | Online Inquiry |
KO26873 | UBQLN2 Knockout cell line (HCT 116) | Human | UBQLN2 | 1:2~1:4 | Negative | Online Inquiry |
KO26874 | UBQLN2 Knockout cell line (HEK293) | Human | UBQLN2 | 1:3~1:6 | Negative | Online Inquiry |
KO26875 | UBQLN2 Knockout cell line (A549) | Human | UBQLN2 | 1:3~1:4 | Negative | Online Inquiry |
UBQLN2 Gene Knockout Cell Lines are advanced cellular models created by inactivating the UBQLN2 gene, which encodes a multifunctional protein involved in protein homeostasis, degradation, and cellular stress responses. These cell lines serve as a vital tool for studying the role of UBQLN2 in various biological processes, including neurodegeneration, cell cycle regulation, and apoptosis. By employing CRISPR-Cas9 or other gene-editing technologies, researchers can efficiently disrupt the gene's expression, enabling the detailed examination of its functions in specific cellular contexts.
The primary mechanism of action of these knockout cell lines revolves around the disruption of the UBQLN2 protein’s normal functioning. This leads to alterations in protein aggregation dynamics and can mimic pathological conditions observed in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The value of these cell lines in research and clinical applications is indispensable, as they provide a unique platform for understanding disease mechanisms, screening therapeutic agents, and validating molecular pathways implicated in health and disease.
What sets our UBQLN2 Gene Knockout Cell Lines apart from traditional models is their unparalleled accuracy and specificity in gene targeting. Unlike knockdown approaches that may yield incomplete gene suppression, our knockout technology ensures a complete loss of gene function. This fidelity enhances the reliability of experimental outcomes, making them attractive for both fundamental and translational research.
For researchers and clinicians, these cell lines are invaluable resources that accelerate the understanding of UBQLN2's role in cellular processes and disease states. The ability to dissect cellular pathways and explore novel interventions holds tremendous promise for innovative therapeutic strategies.
Our company, with a strong commitment to advancing biological research, specializes in providing high-quality, customizable cell lines for the scientific community. We leverage our expertise to ensure that our products meet the evolving demands of researchers, ultimately contributing to significant advances in biomedical science.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.